WS #10945

20:57→21:21 UTC

From 500 msgs · 3 key-dev

BridgeBio announces NEJM publication of Phase 3 PROPEL 3 trial for infigratinib in achondroplasia, showing statistically significant improvements; NDA submission planned for Q3 2026.

BridgeBio Positive Phase 3 Results

BridgeBio announces NEJM publication of Phase 3 PROPEL 3 trial for infigratinib in achondroplasia, showing statistically significant improvements; NDA submission planned for Q3 2026.

Full world state #10945 →